Nitridergic Modulation of the Antinociceptive Activity of Rosuvastatin in Mice

Noriega, Viviana; Sierralta, Fernando; Prieto, Juan Carlos; Zanetta, Pilar; Miranda, Hugo F.

doi:10.4236/pp.2014.51010

Cited by 2 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accordingly, the results of the present study show that rosuvastatin is a molecule capable of inhibiting pain and inflammation. Thus, the findings of this study are in agreement with previous results [2,3,[9][10][11][12][13]. This antinociceptive activity of statins deserves further study since it has been reported that these drugs have contradictory effects: they reduce neuropathic pain in animals but increase it in men.…”

Section: Discussionsupporting

confidence: 92%

Antinociception induced by rosuvastatin in mice: Modulation by opioid receptor antagonists, risperidone and l-name

Juan Carlos Prieto,

Viviana Noriega,

Hugo F Miranda

2024

GSC Adv. Res. Rev.

View full text Add to dashboard Cite

Statins are widely used in cardiovascular disease as cholesterol lowering drugs. However, they also have other actions (pleiotropic effects) including antiproliferative, antithrombotic, neuroprotective, immunomodulatory, anti-inflammatory and antinociceptive activity. The aim of this study was to determine the antinociception properties of rosuvastatin in two murine models of pain and the involvement of opioid antagonists (naltrexone, naltrindole, norbinaltorphimine), risperidone, and L-NAME (L-NG-nitro arginine methyl ester) in this effect. Rosuvastatin was chosen among available statins because it is commonly prescribed and has high potency, efficacy, and an acceptable safety profile. Rosuvastatin antinociception was evaluated in the acetic acid writhing test and the formalin hind paw test by dose-response curves, before and after the i.p. administration of opioid antagonists, risperidone, and L-NAME. This work demonstrates that the assayed drugs modulate the antinociceptive effect of rosuvastatin in both experimental murine pain tests. The antinociception effect described for rosuvastatin may be due to a particular modulation induced by the opioid antagonists, risperidone and L-NAME. Given the broad effects of rosuvastatin, the results of this study may have novel clinical implications in the therapy of pain.

show abstract

Section: Discussionsupporting

confidence: 92%

Antinociception induced by rosuvastatin in mice: Modulation by opioid receptor antagonists, risperidone and l-name

Juan Carlos Prieto,

Viviana Noriega,

Hugo F Miranda

2024

GSC Adv. Res. Rev.

View full text Add to dashboard Cite

show abstract

Experimental evaluation of the antinociceptive and anti-inflammatory effects of rosuvastatin and its interaction with celecoxib and paracetamol

Jawad¹,

Kashmar²

2015

MJBU

View full text Add to dashboard Cite

Background: Studies revealed that statins can result in a larger mortality benefit than can be readily explained by their cholesterol-lowering effect alone. These benefits might be related to the anti-inflammatory and other effects statins may have. Aim: To find out the extent to which rosuvastatin can be considered as an antinociceptive and anti-inflammatory drug in comparison to two standard drugs; paracetamol and celecoxib. Methods: Mice (a total of 132) of either sex, 3-4 weeks of age, 20-25 gm body weight, were used. Tests for nociception: tail flick, hot plate and formalin tests; and for inflammation (formalin for chronic inflammation, carrageenan-induced paw edema, and TNF alpha level in blood) were used. Rosuvastatin (7mg/kg), paracetamol (40mg/kg), celecoxib (6mg/kg) or their combination were administered orally once daily in a volume of 0.2 ml. TNF alpha level in blood was measured using ELISA kit. Results: The antinociceptive effect of rosuvastatin was mild and was much less than that of paracetamol and celecoxib when tested in the tail-flick, hot-plate and formalin tests. It increased the latency for tail flick by only 13.3% when compared to pre-treatment measurements, and in formalin test, it reduced the licking time by 20.9% in comparison to control. The administration of rosuvastatin with either paracetamol or celecoxib did not add to the antinociceptive effects of the latter two drugs except in formalin test for pain. None of the above mentioned drugs reduced hind-paw edema when measured 24 hours after formalin injection, while they produced a significant edema-reducing effect after 14 days. Again there was no additive effect between rosuvastatin and either paracetamol or celecoxib; in contrast, rosuvastatin reduced nearly all the effects of celecoxib when given in combination. Similar trend was found when edema-induced by carrageenan injection. Conclusion: Rosuvastatin showed a significant antinociceptive effect in tail flick and in formalin test, but not in hot plate test in mice. It had anti-inflammatory and edema-reducing effects in models of inflammation but the effect was less than that of celecoxib and even paracetamol. These rosuvastatin effects did not add to those of paracetamol and had caused a reduction in celecoxib effects, when given in combination, except in formalin test for pain where there were additive effect.

show abstract

Nitridergic Modulation of the Antinociceptive Activity of Rosuvastatin in Mice

Cited by 2 publications

References 24 publications

Antinociception induced by rosuvastatin in mice: Modulation by opioid receptor antagonists, risperidone and l-name

Antinociception induced by rosuvastatin in mice: Modulation by opioid receptor antagonists, risperidone and l-name

Experimental evaluation of the antinociceptive and anti-inflammatory effects of rosuvastatin and its interaction with celecoxib and paracetamol

Contact Info

Product

Resources

About